9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet’s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Behçet's disease (BD) is an intractable systemic inflammatory disease characterized by four main symptoms: oral and genital ulcers and ocular and cutaneous involvement. The Japanese diagnostic criteria of BD classify intestinal BD as a specific disease type. Volcano-shaped ulcers in the ileocecum are a typical finding of intestinal BD, and punched-out ulcers can be observed in the intestine or esophagus. Tumor necrosis factor inhibitors were first approved for the treatment of intestinal BD in Japan and have been used as standard therapy. In 2007 and 2014, the Japan consensus statement for the diagnosis and management of intestinal BD was established. Recently, evidence-based JSBD (Japanese Society for BD) Clinical Practice Guidelines for BD (Japanese edition) were published, and the section on intestinal BD was planned to be published in English. Twenty-eight important clinical questions (CQs) for diagnosis (CQs 1–6), prognosis (CQ 7), monitoring and treatment goals (CQs 8–11), medical management and general statement (CQs 12–13), medical treatment (CQs 14–22), and surgical treatment (CQs 23–25) of BD and some specific situations (CQs 26–28) were selected as unified consensus by the members of committee. The statements and comments were made following a search of published scientific evidence. Subsequently, the levels of recommendation were evaluated based on clinical practice guidelines in the Medical Information Network Distribution Service. The degree of agreement was calculated using anonymous voting. We also determined algorithms for diagnostic and therapeutic approaches for intestinal BD. The present guidelines will facilitate decision making in clinical practice.

          Related collections

          Most cited references82

          • Record: found
          • Abstract: found
          • Article: not found

          Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD.

          We aimed to describe the main features of Behçet's disease (BD) in children in the largest prospective cohort to date and to propose a classification.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.

            To report the efficacy and safety of anti-TNF agents in patients with severe and/or refractory manifestations of Behçet's disease (BD).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.

              The efficacy of thiopurines, including azathioprine (AZA) and 6-mercaptopurine (6MP), has been demonstrated for the treatment of inflammatory bowel disease (IBD). The most common and serious adverse event of treatment with thiopurines altered by doctors is leukopenia. Hair loss is also a serious event that could be a critical reason for patients to decline thiopurine treatment. Thiopurine-induced severe hair loss causes cosmetic problems, and it takes a long time to recover. In a recent study, NUDT15 R139C was strongly associated with thiopurine-induced leukopenia in Korean and Caucasian populations. In this study, we performed an association study to investigate and replicate the association of R139C with adverse events of thiopurines in Japanese patients. A total of 142 Japanese patients with IBD, with histories of thiopurine treatment, were examined. NUDT15 R139C was genotyped using a custom TaqMan genotyping assay. Adverse events including leukopenia were reviewed from medical records. The 6MP dose was adjusted to AZA equivalents by multiplying with 2 as a thiopurine dose. Five patients developed severe hair loss and all of them were risk homozygous (T/T) for R139C. No early severe hair loss was observed in patients with the C/T or C/C genotype (P=3.82 × 10(-16), odds ratio=212). The association of R139C with early (<8 weeks) leukopenia (white blood cells<3000 mm(-3)), which was previously reported in Korean patients, was replicated in our Japanese IBD cohort (P=1.92 × 10(-16), odds ratio=28.4). However, we could not confirm the association with late leukopenia in the Japanese subjects. Patients with the C/T genotype discontinued treatment or required thiopurine dose reduction significantly earlier than patients with the C/C genotype (P=1.45 × 10(-4)); however, on manipulating the doses, there was no significant difference in the thiopurine continuation rates between the groups. In the maintenance period, the frequencies of 6MP usage were higher, and the doses of thiopurines were significantly lower in patients with the C/T genotype than in those with the C/C genotype (0.574±0.316 mg kg(-1) per day vs 1.03±0.425 mg kg(-1) per day, P=6.21 × 10(-4)). NUDT R139C was significantly associated with early severe hair loss in Japanese patients with IBD. We also verified the previously reported association of R139C with early leukopenia in a different East Asian population. It is recommended that treatment with thiopurines should be avoided for patients with the T/T genotype. Low-dose 6MP (0.2-0.3 mg kg(-1) per day) could be used rather than AZA for the patients with C/T genotype to continue thiopurine treatments. However, late leukopenia and other several adverse events could not be completely predicted by R139C genotypes.
                Bookmark

                Author and article information

                Contributors
                thisamatsu@ks.kyorin-u.ac.jp
                Journal
                J Gastroenterol
                J. Gastroenterol
                Journal of Gastroenterology
                Springer Singapore (Singapore )
                0944-1174
                1435-5922
                7 May 2020
                7 May 2020
                2020
                : 55
                : 7
                : 679-700
                Affiliations
                [1 ]GRID grid.272264.7, ISNI 0000 0000 9142 153X, Department of Intestinal Inflammation Research, , Hyogo College of Medicine, ; Hyogo, Japan
                [2 ]GRID grid.260433.0, ISNI 0000 0001 0728 1069, Department of Gastroenterology and Metabolism, , Nagoya City University Graduate School of Medical Sciences, ; Aichi, Japan
                [3 ]GRID grid.26091.3c, ISNI 0000 0004 1936 9959, Centers for Preventive Medicine, , Keio University School of Medicine, ; Tokyo, Japan
                [4 ]GRID grid.413045.7, ISNI 0000 0004 0467 212X, Inflammatory Bowel Disease Center, , Yokohama City University Medical Center, ; Kanagawa, Japan
                [5 ]GRID grid.410786.c, ISNI 0000 0000 9206 2938, Research and Development Center for New Medical Frontiers, , Kitasato University, School of Medicine, ; Kanagawa, Japan
                [6 ]GRID grid.265073.5, ISNI 0000 0001 1014 9130, Department of Gastroenterology and Hepatology, , Tokyo Medical and Dental University, ; Tokyo, Japan
                [7 ]GRID grid.63906.3a, ISNI 0000 0004 0377 2305, Division of Gastroenterology, , National Center for Child Health and Development, ; Tokyo, Japan
                [8 ]GRID grid.272264.7, ISNI 0000 0000 9142 153X, Department of Inflammatory Bowel Disease, Division of Surgery, , Hyogo College of Medicine, ; Hyogo, Japan
                [9 ]GRID grid.417366.1, ISNI 0000 0004 0377 5418, Department of Inflammatory Bowel Disease, , Yokohama Municipal Citizen’s Hospital, ; Kanagawa, Japan
                [10 ]GRID grid.415395.f, ISNI 0000 0004 1758 5965, Center for Advanced IBD Research and Treatment, , Kitasato University Kitasato Institute Hospital, ; Tokyo, Japan
                [11 ]GRID grid.459842.6, ISNI 0000 0004 0406 9101, Department of Allergy and Rheumatology, , Nippon Medical School Musashi Kosugi Hospital, ; Kanagawa, Japan
                [12 ]Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kanazawa, Japan
                [13 ]GRID grid.411790.a, ISNI 0000 0000 9613 6383, Division of Gastroenterology, Department of Medicine, , Iwate Medical University, ; Iwate, Japan
                [14 ]GRID grid.268441.d, ISNI 0000 0001 1033 6139, Department of Ophthalmology and Visual Science, , Yokohama City University Graduate School of Medicine, ; Kanagawa, Japan
                [15 ]GRID grid.265050.4, ISNI 0000 0000 9290 9879, Inflammatory Bowel Disease Center, , Toho University Sakura Medical Center, ; Chiba, Japan
                [16 ]GRID grid.411205.3, ISNI 0000 0000 9340 2869, Department of Gastroenterology and Hepatology, , Kyorin University School of Medicine, ; Tokyo, Japan
                Article
                1690
                10.1007/s00535-020-01690-y
                7297851
                32377946
                3be22ef0-544c-475c-8aa2-9c5eb89db005
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 25 February 2020
                : 8 April 2020
                Categories
                Original Article—Alimentary Tract
                Custom metadata
                © Japanese Society of Gastroenterology 2020

                Gastroenterology & Hepatology
                intestinal behçet’s disease,guideline,evidence,consensus,behçet’s disease

                Comments

                Comment on this article